These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15708534)

  • 1. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
    Blanchard F; Chipoy C
    Drug Discov Today; 2005 Feb; 10(3):197-204. PubMed ID: 15708534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages.
    Han SB; Lee JK
    Arch Pharm Res; 2009 Apr; 32(4):613-24. PubMed ID: 19407980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
    Huang L
    J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
    Glauben R; Siegmund B
    Methods Mol Biol; 2009; 512():365-76. PubMed ID: 19347289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
    Kim HM; Ryu DK; Choi Y; Park BW; Lee K; Han SB; Lee CW; Kang MR; Kang JS; Boovanahalli SK; Park SK; Han JW; Chun TG; Lee HY; Nam KY; Choi EH; Han G
    J Med Chem; 2007 May; 50(11):2737-41. PubMed ID: 17477518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinazolines as novel anti-inflammatory histone deacetylase inhibitors.
    Lin Z; Murray PM; Ding Y; Denny WA; Ferguson LR
    Mutat Res; 2010 Aug; 690(1-2):81-8. PubMed ID: 20558185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cellular radiation responses by histone deacetylase inhibitors.
    Karagiannis TC; El-Osta A
    Oncogene; 2006 Jun; 25(28):3885-93. PubMed ID: 16462761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitors in models of inflammation-related tumorigenesis.
    Glauben R; Sonnenberg E; Zeitz M; Siegmund B
    Cancer Lett; 2009 Aug; 280(2):154-9. PubMed ID: 19101082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors: multifunctional anticancer agents.
    Liu T; Kuljaca S; Tee A; Marshall GM
    Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
    Hu J; Colburn NH
    Mol Cancer Res; 2005 Feb; 3(2):100-9. PubMed ID: 15755876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC Inhibitors--CHI's Third Annual Conference.
    Rosato RR
    IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.